Characteristics of colorectal patients who discontinued oxaliplatin therapy.

被引：1
|
作者：
Buchholz, Alexander
Sahmoun, Abe E.
Kurniali, Peter C.
机构：
[1] Univ North Dakota, Sch Med & Hlth Sci, Grand Forks, ND USA
[2] Univ North Dakota, Sch Med & Hlth Sci, Fargo, ND USA
[3] Univ North Dakota, Sch Med & Hlth Sci, Sanford Canc Ctr, Bismarck, ND USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 15期
关键词：
D O I：
10.1200/JCO.2019.37.15_suppl.e15155
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15155
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Outcome of chronic hepatitis B patients who discontinued nucleos(t)ide analogue therapy
    Yapali, Suna
    Oberhelman, Kelly
    Lok, Anna S.
    HEPATOLOGY, 2014, 60 : 1114A - 1115A
  • [22] Platinum deposition in skin as a possible mechanism for peripheral sensory neuropathy (PSN) in patients (pts) with colorectal cancer (CRC) following oxaliplatin-based therapy.
    Cao, Yanshuo
    Chang, Qing
    Zhang, Wenjiang
    Ornatsky, Olga
    Chen, Eric Xueyu
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [23] Real-world outcomes with fedratinib therapy in patients who discontinued ruxolitinib for primary myelofibrosis
    Passamonti, Francesco
    Lou, Youbei
    Chevli, Manoj
    Abraham, Pranav
    FUTURE ONCOLOGY, 2024, 20 (17) : 1165 - 1174
  • [24] Clinical characteristics and risk factors for oxaliplatin hypersensitivity reactions in patients with colorectal cancer
    Kim, Jeong Hye
    Jung, Mi Kyoung
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2025, 31 (01) : 17 - 21
  • [25] Incidence of peripheral neuropathy in patients with colorectal cancer receiving oxaliplatin alone vs. radiation therapy and oxaliplatin
    Lockwood, Matthew Blake
    Joshi, Krishna Prasad
    Mobley, James
    Sampath, Suneetha
    Siegel, Eric R.
    Govindarajan, Rangaswamy
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [26] CAPECITABINE AND OXALIPLATIN (CAPOX) PLUS CETUXIMAB IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA WHO PROGRESSED AFTER OXALIPLATIN-BASED CHEMOTHERAPY
    Petrovic, Z.
    ANNALS OF ONCOLOGY, 2008, 19 : 135 - 135
  • [27] The role of oxaliplatin in the therapy for advanced colorectal carcinoma
    Nehls, O
    Porschen, R
    Gregor, M
    Klump, B
    ZEITSCHRIFT FUR GASTROENTEROLOGIE, 2001, 39 (12): : 1033 - 1047
  • [28] Who makes the decision to receive Oxaliplatin among stage III colorectal cancer (CRC) patients?
    Hassan, Syreen
    Miles, Anne
    Morris, Melanie
    PSYCHO-ONCOLOGY, 2019, 28 : 18 - 19
  • [29] Cosmesis from the viewpoint of patients who underwent breast-conserving therapy.
    Nakayama, H
    Tokuuye, K
    Kakuta, N
    Morishima, I
    Tanaka, Y
    Mitsuhashi, S
    Ishikawa, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 766S - 766S
  • [30] CHARACTERISTICS OF PATIENTS WHO DISCONTINUED BARICITINIB TREATMENT WITHIN 12 MONTHS AND REASONS FOR DISCONTINUATION: REALWORLD DATA
    Lwin, May Nwe
    Holroyd, Christopher
    Edwards, Christopher J.
    RHEUMATOLOGY, 2021, 60 : 5 - 5
12345